ARD launches an advanced online publication programme

L van de Putte

Selected papers will be published within days of acceptance

ARD Online First is an exciting innovation that will allow publication of selected articles within days of acceptance, and therefore months before they appear in the print version of the Annals of the Rheumatic Diseases. From February 2004 selected articles will appear in the raw manuscript form (not edited or typeset) in a new section on the ARD website (http://www.annrheumdis.com) indicated by the Online First logo (fig 1).

WHY DO WE NEED ONLINE FIRST?

Most medical journals have considerable delays between manuscript acceptance and publication in print, sometimes longer than a year. For practical reasons, at least some of this delay is unavoidable. However, we all agree that important clinical and scientific data should be available as soon as possible, especially where the information may impact clinical care. Advanced online publication goes some way towards meeting this need.

Figure 1 ARD Online First logo.

HOW WILL ONLINE FIRST WORK?

During the initial phase, we (the editorial team) will select two or three articles a week for advanced publication. The selection process aims at choosing papers with particular impact for clinicians, patients, and researchers. Authors will be asked for their permission to be part of ARD Online First and they will have an opportunity to proof the manuscript as usual before publication in the journal. The unedited manuscripts will be published weekly; edited, typeset versions may be posted as they become available. The final print version will be stamped with the ARD Online First logo (fig 1) and it will be high-lighted on the table of contents within the issue. The ultimate print version will include the date of the initial online publication and all versions will be linked online. All articles are assigned a unique code—digital object identifier (DOI)—and guidance on how to cite the article will appear on the website.

Online First articles will be indexed by PubMed/Medline within days of publication, establishing primacy for the work. They will be searchable through the usual search engines (PubMed, Google, etc) and through ARD Online; search results will default to the most recent version.

Annals of the Rheumatic Diseases is the first of the specialist journals published by the BMJ Publishing Group (http://www.bmjjournals.com) to launch an Online First programme (the weekly BMJ started its advanced online publication section in December 2003). ARD Online First is an experiment and we welcome comments from authors and readers—both positive and critical—so that we can optimise the service and accompanying procedures. If the pilot is deemed a success the programme may be expanded so that most accepted articles are available Online First.

We are confident that this exciting new feature will be valued by all who may profit from ARD, including clinicians, researchers, and, last but not least, patients.

Ann Rheum Dis 2004;63:221

REFERENCE


FUNCTIONAL ASSESSMENT BY SELF REPORT QUESTIONNAIRES

Functional assessment by self report questionnaires has become standard in randomised clinical trials15–17 as well as clinical research. The most commonly used among the many questionnaires18 is the Stanford Health Assessment Questionnaire (HAQ)19 and its derivatives. These questionnaires measure primarily function and health related quality of life, the improvement of which is the most important aspect in the care for our patients. Nevertheless, these questionnaires do not allow differentiation between the degree to which an impairment in functional activity is due to current disease activity (and thus is process related and poten-
or infliximab (54 week trial) in patients with long established RA, baseline HAQ scores were 1.5 or 1.8, respectively, and improvement amounted to about 45% and 30%, while the placebo responses were about 25% and 10%; mean disease duration was about 13 and 11 years, respectively.\(^{22-25}\) In a 24 week trial of leflunomide, in which starting HAQ scores were 1.1 at baseline, improvement by about 45% was seen with leflunomide compared with 30% with sulfasalazine and <10% with placebo; mean disease duration in that population was about 7 years.\(^{26}\) Changes with anakinra treatment fall into about the same range.\(^{31}\)

Trials cannot be compared easily owing to differences in the patient groups investigated. Nevertheless, several lines of information can be drawn from these trials\(^{26-32}\) as well as from observational studies\(^{24-25}\):

- **DMARD treatment improves HAQ scores significantly.** Over the course of 6 months to 2 years, the usual duration of these trials and their extensions, HAQ scores do not deteriorate in patients with highly active disease, even if treated with placebo; rather, they often improve slightly with placebo, and, therefore, an improvement of more than ~0.22 has been determined as minimum important difference.\(^{33-35}\) With treatment with DMARDs or biological agents, HAQ improves by more than ~0.5 in many patients, in some trials even in >50% of the patients.\(^{36}\) This degree exceeds more conservative results on the significant change of the HAQ from the patients’ perspective in clinical settings, which amounts to at least ~0.31 at an 80% confidence level, and at least ~0.48 for 95% confidence.\(^{37}\) Thus, effective DMARD treatment affects the HAQ score significantly, whether in clinical trials or practice, but even with placebo there is some improvement in HAQ in clinical trials, although this rarely exceeds the minimum important difference on a group level. (In this respect it is important to mention that laboratory surrogates of disease activity, such as C reactive protein (CRP), usually decrease significantly with effective DMARD treatment but show little or no change with placebo.)

- **Structural damage does not impact HAQ scores in the shorter term.** Because radiographic changes deteriorate significantly in placebo treated patients, these destructive events are not reflected in a deterioration of HAQ scores and thus do not lead to an impairment of functional activities in the relatively short term. This conclusion is in line with the findings, that joint destruction impacts HAQ scores mainly in the long term—that is, as a consequence of its accumulation over time.\(^{12-24\text{,}25}\) It also indicates that despite their significant rise, increases of radiographic scores over the time followed in clinical trials are too small to affect function. Moreover, HAQ scores are related more to destruction of large joints than to those of small joints,\(^{24}\) and the large joints are usually not evaluated for radiographic changes in clinical trials.

- **Structural damage does impact HAQ scores in the longer term.** Comparing HAQ scores and disease duration in different trials at baseline, one might extrapolate that among patients fulfilling the entry criteria for clinical trials, disability scores increase with increasing disease duration (and increasing numbers of DMARD failures). Moreover, despite the significant effects of all these treatments on disease activity, the association of HAQ scores with disease duration was maintained even at the end of the trials: approximate HAQ scores at study end were 0.9 in the etanercept/MTX trial, 1.3 in the infliximab/MTX trial, and 0.6 in the leflunomide trial, whereas—after one year of traditional DMARD treatment—amounted to 0.5 in patients in whom DMARDs were started at a median of about 12 months’ disease duration and to 0.2 in those in whom treatment was started within about 3 months (and <5 months) from onset of symptoms. Thus, with increasing disease duration the deterioration of the HAQ score determined by disease activity shrinks compared with that determined by irreversible changes in patients with long term RA. These findings extrapolated from recent clinical trials are in line with the prospective data on the association of HAQ with long term radiographic damage.\(^{12-24\text{,}25}\)

- **HAQ scores reflect disease activity to an important extent.** It appears—on the basis of the above trial patient groups—that about 0.3–0.7 HAQ score units are governed by disease activity. It should be noted that such extrapolation from trial data refers to mean values, that remissions are only rarely seen in clinical trials, and that, consequently, further reduction of disease activity may lead to even more reduction in HAQ scores. Moreover, changes in HAQ score may vary in different individual patients. However, these data indicate that,
regardless of duration of disease, the HAQ score does partly reflect disease activity and this to an important extent. 28 29 37

- The proportionate contribution of disease activity and damage to total HAQ scores is unknown. Given that the HAQ is an important outcome in most clinical trials on new therapeutic drugs, it should be borne in mind that these trials provide a rather short time view of treatment effects. Although retardation or even arrest of progression of destruction can be shown in many patients in such trials, such retardation would have to be over a long period of time, rather than the usual one year time-frame of radiographic studies in clinical trials, to materialise into clinical benefit, and thus the essential variable (and target) of most short term treatments is disease activity. Therefore, the proportion of the HAQ score that is primarily explained by disease activity, determines the therapeutic potential. It would be most desirable to estimate the impact of disease activity on function or quality of life, maybe by deduction of an activity adjusted HAQ score; vice versa, such a score could allow deduction of a measure for the impact of accrued damage on function or quality of life. In a group comparison, changes in such a score would better reflect the effects of an intervention on damage related impairment.

"The proportion of the HAQ score that is explained by disease activity determines the therapeutic potential"

EVALUATION OF DISEASE ACTIVITY

ACR criteria, DAS, and EULAR response criteria

For the evaluation of disease activity, a combination of surrogates related directly to the inflammatory events, such as joint counts and the acute phase response, have been successfully employed over the past decade. 11 27 48–52 Although the American College of Rheumatology (ACR) response criteria have been developed to compare improvement from baseline in cohorts of patients, they do not allow assessment of "actual" disease activity, and thus neither comparison of clinical status between groups of patients nor between individual patients is possible. In contrast, the employment of a numerical measure from baseline throughout the disease course, as provided by the DAS and the EULAR response criteria, allows a comparison of the disease status of patient cohorts as well as individual patients. 71 72 This is an important advantage, if disease activity measures are to be successfully employed in clinical practice. Nevertheless, calculation of the DAS, and also of the ACR response, is relatively complicated and requires the use of a calculator. Therefore, simpler activity indices could be of particular help to allow transfERENCE of activity scoring into daily clinical practice.

Simplified disease activity index (SDAI)

Aiming at obtaining a simple disease activity measure, we have recently developed the simplified disease activity index (SDAI), which is the linear sum of five core set variables: tender joint and swollen joint count based on a 28 joint assessment, patient and physician global assessment of disease activity, and CRP. Changes to the SDAI are found to correlate very well with changes of the DAS, of the ACR response, and also with HAQ scores and radiographic changes. Furthermore, a truncated SDAI, summing the values of all variables with the exception of CRP, 73 was equally reliable, allowing a validated disease activity measure to be obtained during the office visit of the patient, without having to wait for a laboratory result. Thus, tools are available to document patients' disease activity simply and reliably, whether by using only a patient questionnaire 74 or a combination of questions to the patient and physician's assessment, such as the SDAI. 73 Also, the calculation of the DAS has become simpler because an automated calculator has become available. However, it should be borne in mind that validation
of response criteria has been mostly obtained using data of clinical trials. Thus, more validation is required before response criteria are fully adopted for clinical practice. In such research their value for daily practice settings will be best assessable. To this end, the measurement error of assessing joint counts or using health status measures repeatedly needs to be taken into account, 41–43 51 and in clinical practice a definite improvement or deterioration could be defined as a change that exceeds such measurement error.

ADVERSE EVENTS

The follow up of patients also requires looking for adverse events. Interestingly, laboratory abnormalities tend to occur mainly during the first 3 to 4 months of DMARD treatment and are much rarer during subsequent months 64; thus, once patients have tolerated DMARDs for 4 months or more, tight laboratory monitoring does not appear to be necessary.

“Most adverse events occur during the first few months of DMARD treatment”

SUMMARY

Taken together, our current clinical armamentarium to follow the course of RA offers several disease activity measures. Evaluation of radiographic destruction, but also of anatomical changes such as malalignment, 65 can serve as outcome measure, because these changes best reflect the damage related to the pathological process in and around the joints; whether radiological changes can be reversible, is still a matter of debate. 66 Assessment of function reflects the combination of disease activity and damage. Questionnaires or other instruments which only determine functional improvement due to irreversible damage are not (yet) available. However, their development could lead to interesting, new clinical insights. Likewise, basic science has not yet provided us with tests that reflect the destructive process reliably. Measuring disease activity by surrogate measures such as the acute phase proteins does not reflect destruction at a single point in time.

In conclusion, assessment of disease activity, damage, and functional capacity are equally important also in clinical practice: RA, if insufficiently controlled, may be a highly destructive disease. Achieving low disease activity, ideally a remission-like state, is pivotal to improving prognosis. 67 Current treatments and early institution of DMARDs allow this aim to be accom-

- plished in many patients. However, decisions to switch (or to maintain) treatment require recording of the patients’ clinical status, and in many healthcare systems the use of costly treatments, as increasingly employed, requires justification which, again, can only come from recorded data. 68 Rather than guessing disease activity and quality of life, providing evidence will validate decisions and improve quality of care. A combination of a more physiological center such as the Ankylosing Spondylitis Disease Activity Index 69,70 or similar, with a patient centred functional measure, such as the HAQ or similar, in conjunction with an occasional evaluation of the radiographic situation, will give all necessary information for the longitudinal observation of patients’ disease state in clinical practice. The tools are available and so relatively easy to use.


Authors’ affiliations

J S Smolen, D Arbogast, Department of Rheumatology, Internal Medicine III, Vienna General Hospital, University of Vienna, and 2nd Department of Medicine, Lainz Hospital, Vienna, Austria

Correspondence to: Professor J S Smolen, University of Vienna, Div of Rheumatology, Department of Internal Medicine III University of Vienna, Vienna General Hospital Vienna, A-1090, Austria; josef.smolen@vienkov.at

REFERENCES

6 Harrison BJ, Symmons DP. Early inflammatory polyarthritis: results from the Norfolk Arthritis Register with a review of the literature. II. Outcome at three years. Rheumatology (Oxford) 2000;39:939–49.
28 Weinblatt ME, Kremer JM, Burmehrt AD, Sulzht JK, Fleischman RN, Fox RJ, et al. A trial of etanercept, a recombinant tumor necrosis factor a


www.annrheumdis.com
Patients with rheumatoid arthritis in clinical care

J S Smolen and D Aletaha

*Ann Rheum Dis* 2004 63: 221-225
doi: 10.1136/ard.2003.012575

Updated information and services can be found at: http://ard.bmj.com/content/63/3/221.2

*These include:*

**References**

This article cites 72 articles, 23 of which you can access for free at: http://ard.bmj.com/content/63/3/221.2#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Connective tissue disease (4253)
- Degenerative joint disease (4641)
- Immunology (including allergy) (5144)
- Musculoskeletal syndromes (4951)
- Rheumatoid arthritis (3258)
- Inflammation (1251)

**Notes**

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/